Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome

Diabetic Medicine

Volumn 24, Issue 3, 2007, Pages 272-279

  Kraemer De Aguiar, L G ^a,b   Laflor, C M ^a   Bahia, L ^a   Villela, N R ^a   Wiernsperger, N ^a   Bottino, D A ^a   Bouskela, E ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Metabolic syndrome; Metformin; Microvascular disease; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTERY OCCLUSION; ARTICLE; BIOCHEMISTRY; BLOOD FLOW VELOCITY; BLOOD SAMPLING; BLOOD VESSEL DIAMETER; BLOOD VESSEL REACTIVITY; BODY MASS; BODY WEIGHT; CAPILLAROSCOPY; CAPILLARY DENSITY; CAPILLARY FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MEDICAL PARAMETERS; METABOLIC SYNDROME X; MICROCIRCULATION; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RELATIVE; REST; SKIN BLOOD FLOW; SKIN CAPILLARY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS;

ADULT; CAPILLARIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; MICROCIRCULATION; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; SKIN;

EID: 33847006929     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02082.x     Document Type: Article

References (47)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and managment of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
2. Hubert HB, Feinleib M, McNamara PM, Castelli HP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
3. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-889.
4. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002; 25: 1320-1325.
5. de Jongh PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, for the Prevend Study Group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26: S21-S24.
6. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
7. Jang Y, Kim OY, Ryu HJ, Kim JY, Song SH, Ordovas JM et al. Visceral fat accumulation determines postprandial lipemic response, lipid peroxidation, DNA damage, and endothelial dysfunction in nonobese Korean men. J Lipid Res 2003; 44: 1356-1364.
8. Balletshofer BM, Rittig K, Enderle M, Volk A, Maerker E, Jacob S et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
9. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-1862.
10. Jörneskorg G, Kalani M, Kuhl J, Bavenholm P, Katz A, Allerstrand G et al. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care 2005; 28: 1495-1497.
11. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: 9S-13S.
12. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The Common Soil Hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
14. Bae JH, Bassenge E, Kim YN, Kim KB, Kim KS, Lee HJ et al. Post-prandial hypertrigliceridemia impairs endothelial function by enhanced oxidant stress. Atheroschlerosis 2001; 155: 517-523.
15. Redon J, Olivia MR, Tormos C, Giner V, Chaves J, Iradi A et al. Antioxidant activities and oxidative stress by products in human hypertension. Hypertension 2003; 41: 1096-1101.
16. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 1988; 5: 113-124.
17. Kerney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23: 434-439.
18. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Tech Therap 2000; 2: 259-272.
19. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabet Med 2003; 29: 6S44-6S52.
20. Knowler WC, Barret-Connor E, Fowler SE, Hamman RF, Larchin JM, Walker EA et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
22. Ming-Hui Z, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles 4th WG, Schlattner U et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo - role of mitochondrial reactive nitrogen species. J Biol Chem 2004; 279: 43940-43951.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.
24. Klyscz T, Jünger M, Jung F, Zeintl H. Cap Image - ein neuartiges computerunterstütztes Videoanalysessystem für die dynamische Kapillarmikroskopie. Biomed Technik 1997; 42: 168-175.
25. Katakam PVG, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000; 35: 108-112.
26. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
27. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GMC. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258: 2005.
28. Kraemer de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29: 1083-1089.
29. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC et al. Flow-induced vasodilation of the human brachial artery is impaired in patients < 40 years of age wtih coronary artery disease. Am J Cardiol 1996; 78: 1210-1214.
30. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndrome. Circulation 2004; 110: 1926-1932.
31. Sirtori CR, Franceschini G, Gianfransceschi G. Metformin improves peripheral vascular flow in normohyperlipidemic patients with arterial disease. J Cardiovascular Pharmacol 1984; 6: 914-923.
32. Fagrell B, Fronek A, Intaglietta M. Capillary flow velocity during rest and post occlusive reactive hyperemia in skin areas of the toe and lower leg. Bibl Anat 1977; 16: 159-161.
33. Muntzel MS, Abe A, Petersen JS. Effects of adrenergic, cholinergic and ganglionic blockade on acute depressor responses to metformin in spontaneously hypertensive rats. J Pharmacol Exp Ther 1997; 281: 618-623.
34. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590.
35. Ingelsson E, Ärnlöv J, Sundströn J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005; 46: 2054-2060.
36. Quinones MJ, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 2004; 140: 700-708.
37. Topcu S, Tok D, Caliskan M, Ozciment EE, Gullu U, Uckuyu A, Endorgan D et al. Metformin therapy improves coronary microcirculation function in patients with policystic ovary syndrome and insulin resistance. Clin Endocrinol 2006; 65: 75-80.
38. Wiernesperger N, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab 2003; 29: 6S77-6S87.
39. Serné EH, Ijzerman RG, Gans ROB, Nijveldt R, De Vries G, Evertz R et al. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 2002; 51: 1515-1522.
40. de Jongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CDA. Impaired microvascular function in obesity. Implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535.
41. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177-269.
42. Wiernesperger N. Defects in microvascular haemodynamics during prediabetes: contributor or epiphenomenon? Diabetologia 2000; 43: 1439-1448.
43. Jaap AJ, Shore JE, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997; 40: 238-243.
44. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al. The Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005; 142: 611-619.
45. de Jongh RT, Serné EH, Ijzerman RG, de Vries G. Free fatty acid levels modulate microvascular function. Relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 2004; 53: 2873-2882.
46. Musiek ES, Huiyong Y, Milne GL, Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 2005; 40: 987-994.
47. Janssen LJ. Are endothelium-derived hyperpolarizing and contracting factors isoprostanes? Trends Pharmacol Sci 2002; 23: 59-62.